Kiniksa Pharmaceuticals International, plc
Kinikska Pharmaceuticals International, plc (NASDAQ: KNSA) is a biopharmaceutical company focused on developing and commercializing novel therapies for diseases with unmet medical need, particularly cardiovascular indications. The company's website is www.kiniksa.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Kiniksa Pharmaceuticals International, plc does
In the company’s own words
Kinikska Pharmaceuticals International, plc (NASDAQ: KNSA) is a biopharmaceutical company focused on developing and commercializing novel therapies for diseases with unmet medical need, particularly cardiovascular indications. The company's website is www.kiniksa.com.
The company's primary commercial product is ARCALYST, an interleukin-1 alpha and interleukin-1 beta cytokine trap licensed from Regeneron Pharmaceuticals. ARCALYST received FDA approval in March 2021 for treating recurrent pericarditis and reduction in recurrence risk in adults and children 12 years and older. The drug is also approved for treating Cryopyrin-Associated Periodic Syndromes and maintaining remission in Deficiency of Interleukin-1 Receptor Antagonist. ARCALYST is distributed through a select network of specialty pharmacies across the United States, with Kinikska responsible for sales and distribution while splitting profits with Regeneron. The company granted exclusive rights to develop and commercialize ARCALYST in the Asia Pacific region to Hangzhou Zhongmei Huadong Pharmaceutical in 2022.
Kinikska's pipeline includes several clinical and preclinical stage candidates. KPL-387 is an investigational monoclonal antibody targeting IL-1 receptor 1, currently in Phase 2 development for recurrent pericarditis with potential for monthly subcutaneous self-administration. KPL-1161, a modified version of KPL-387 designed for quarterly dosing, is in preclinical development with plans to initiate Phase 1 trials by end of 2026. Abiprubart, an investigational CD40-CD154 costimulatory interaction inhibitor, had development discontinued in Sjögren's Disease in February 2025, with the company exploring strategic alternatives for the asset.
The company does not operate manufacturing facilities but relies on third-party contract development and manufacturing organizations, with Regeneron currently supplying ARCALYST. Kinikska is conducting a technology transfer of ARCALYST drug substance manufacturing to Samsung Biologics. The company maintains a specialized cardiology sales team and has established collaborative study agreements, including a December 2024 agreement with Mayo Clinic and Johns Hopkins University to investigate ARCALYST for cardiac sarcoidosis treatment.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- LONDON
- Fiscal year end
- December
- CIK
- 1730430
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Kiniksa Pharmaceuticals International, plc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Kiniksa Pharmaceuticals International, plc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Kiniksa Pharmaceuticals International, plc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Kiniksa Pharmaceuticals International, plc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Kiniksa Pharmaceuticals International, plc's last four quarterly filings that the numbers alone won't show?”